12th International Conference on Cochlear Implants and Other Implantable Auditory Technologies
Thursday, May 3, 2012 Scientific Session III Oral Abstracts 3:00 PM – 5:00 PM
Topic:
Outcomes
Title:
Six Years of Experience with a Totally Implantable Cochlear Implant
Author(s):
Robert J Briggs, Helmut Eder, Peter M Seligman, Kerrie L Plant, John M Heasman, Robert C Cowan, Michelle R Knight, James Dalton, James Patrick
Presenter:
Robert J Briggs
Abstract:
Objectives To review the benefits, limitations and technical capability of a prototype totally implantable cochlear implant following six years experience at the HEARing CRC. Study Design The totally implantable implant has a lithium ion rechargeable battery, a package-mounted internal microphone and sound processing electronics that enable the use of ‘Invisible Hearing’ without the use of an external microphone. The implant also functions with an externally worn sound processor as a conventional cochlear implant. The three implanted subjects have used the device in both Invisible Hearing and standard modes of operation since the time of implantation. Hearing performance, patterns of device use, and reports of body noise have been closely monitored. In addition, technical data has been collected to assess the performance of the implantable battery and microphone. Results There have been no surgical or medical post-operative complications associated with use of the device. Although speech perception using Invisible Hearing mode is poorer than that obtained in the conventional mode, all subjects report some benefit associated with use of Invisible Hearing in their daily lives. Two subjects report that they are never without hearing, with Invisible Hearing used at all times when the external device is removed. Specific benefits have been reported, including use of the device when swimming and in providing sound awareness when sleeping. Limitations of the device occur as a result of body noise, and there has been no evidence of habituation to body noise over the six years of use.
The rechargeable battery continues to function well, with a cycle time indicating that the low-power implant design is effective.Conclusion After six years use of the totally implantable system, the device continues to function well and recipients continue to report benefit associated with use of the device. This experience has provided important insight into the potential of such a system.
Otologics Phase 2 clinical trials
Otologics Fully Implantable Hearing Device Phase II Results
Drew M Horlbeck, MD (presenter)
Herman A Jenkins, MD
Ben J Balough, MD
Michael E Hoffer, MD
Abstract
Objective The efficacy of the
Otologics Fully Implantable Hearing Device (MET) was assessed in adult patients with bilateral moderate to severe sensorineural hearing loss.
Methods Surgical insertion of this totally implanted system was identical to the Phase I study. A repeated-measures within-subjects design assessed aided sound field thresholds and speech performances with the subject's own, appropriately fit, walk-in hearing aid(s) and the Otologics Fully Implantable Hearing Device.
Results Six- and 12-month Phase II data will be presented. Ten patients were implanted and activated as part Phase II clinical trial. Three patients were lost to long term follow-up due to two coil failures and one ossicular abnormality preventing proper device placement.
No significant differences between preoperative (AC = 59 dB, BC = 55 dB) and postoperative (AC = 61 dB, BC = 54 dB) unaided pure tone averages were noted (p < 0.05). Pure tone average implant aided thresholds (41 dB) were equivalent to that of walk-in-aided (37 dB) condition with no significant difference (p < 0.05) between patients’ walk-in-aided individual frequency thresholds and implant-aided thresholds. Word recognition scores and hearing in noise scores were similar between the walk-in-aided and for the implant-aided condition. Patient benefit scales will be presented at all end points.
Conclusions
Results of the Otologics MET Fully Implantable Hearing Device Phase II trial provide evidence that this fully implantable device is a viable alternative to currently available hearing aids in patients with sensorineural hearing loss.
This is the Implantable microphone for the Totally Implantable CI
Cochlear buys patent rights for Otologics
From: AAP
September 09,
2009 10:00AM
HEARING implant company Cochlear has secured a license agreement to purchase patent rights, know-how as well as joint development activities with Otologics LLC for $US25 million ($29.02 million).
The agreement with the Colorado-based company
will allow the company to use Otologics' technology with cochlear implants.
Cochlear chief executive Chris Roberts said the purchase was another step toward achieving the company's long term goal of developing a totally implantable cochlear implant.
"This will further expand our product range and reinforce our technologic leadership,'' Dr Roberts said.
"The purchase is particularly useful in the complex area of implantable microphones, vital for the development of a totally implantable cochlear implant.''
The purchase price of $US25 million is payable by the end of calendar 2011, plus a royalty on future net sales of certain products involving an implantable microphone.
Cochlear said the payment will be treated as acquired intangibles and amortised over approximately 15 years.
About $US8.5 million of the purchase price was paid by June 30 this year.